Chair: W. Eberhardt, DE; S. Peters, CH. 12:00-13:00 Industry Satellite Symposium 1 (TBC) Room A. 13:30-13:45 Opening and Welcome Room B
|
|
|
- Allen Lucas
- 5 years ago
- Views:
Transcription
1 :00-13:00 Industry Satellite Symposium 1 (TBC) Room A 13:30-13:45 Opening and Welcome Room B Chair: W. Eberhardt, DE; S. Peters, CH 13:45-14:15 Heine H. Hansen Award Lecture Room B 14:30-16:00 SCLC: Advances and state of the art Room B 14:30-14:45 Staging update on SCLC A. Nicholson, UK 14:45-15:05 Genetics and genetic targets in SCLC J. Poirier, NY/US 15:05-15:20 Translational studies in SCLC M. Edelman, MD/US 15:20-15:35 Advances in systemic treatment of SCLC excluding immunotherapy K. Kubota, JP 15:35-15:50 Radiation therapy in SCLC B. Slotman, NL 15:50-16:00 Questions and Answers
2 14:30-16:00 Mesothelioma: An update Room A 14:30-14:50 New markers in distinguishing reactive from neoplastic mesothelial proliferations S. Lantuejoul, FR 14:50-15:10 Surgical options for patients with mesothelioma in 2016 W. Weder, CH 15:10-15:30 Non-surgical treatment options for mesothelioma P. Baas, NL 15:30-15:50 Genetic profiling and the impact of future therapy of mesotheliomas D. Fennell, UK 15:50-16:00 Questions and Answers 16:00-16:30 Coffee break Hall 1 16:30-18:00 Targeting T790M Room B 16:30-16:50 Advancing technology on blood-based testing for detection of T790M J. Wang, CN 16:50-17:10 A new era of T790M inhibition T.S.K. Mok, CN 17:10-17:30 Mechanism of resistance to T790M inhibitors S. Ramalingam, GA/US 17:30-17:50 T790M inhibitor as first line therapy: Promises and pitfalls J.-C. Soria, FR 17:50-18:00 Questions and Answers
3 16:30-18:00 Oligometastatic NSCLC Room A 16:30-16:50 Overview: Incidence and literature on surgical and ablative approaches F. Mornex, FR 16:50-17:10 Oligometastatic NSCLC with driver mutations: Guidelines and practical application L. Shun, CN 17:10-17:30 Oligometastatic NSCLC without driver mutations: New developments, including immunotherapy E. Smit, NL 17:30-17:50 Surgery in oligometastatic disease Y.L. Wu, CN 17:50-18:00 Questions and Answers 18:30-20:00 Industry Satellite Symposium 2 (TBC) Room A :00-08:50 Optimizing the use of TKI in oncogene addicted NSCLC Room A 08:00-08:15 Treatment of EGFR mutation patients K. O'Byrne, AU 08:15-08:30 Treatment of ALK positive tumours B. Solomon, AU 08:30-08:50 Discussion 08:00-08:50 Young Oncologists session (Title TBC) Room X
4 08:00-08:50 Stereotactic radiotherapy for metastatic NSCLC Room W 08:00-08:15 Checkpoint inhibition: a perspective and a glimpse into the future L. Gaspar, CO/US 08:15-08:30 SBRT in the oligo-metastatic setting: Multiple targets and combination with systemic treatment J. Widder, NL 08:30-08:50 Discussion 09:00-10:30 Targeting ALK Room B 09:00-09:20 Science overview, mechanisms of resistance C. Lovly, TN/US 09:20-09:40 Practical management of ALK mutation patients S. Novello, IT 09:40-10:00 Clinical trials with novel agents B. Solomon, AU 10:00-10:20 Sequencing of agents M. Perol, FR 10:20-10:30 Questions and Answers 09:00-10:30 Smoking prevention and cessation Room C 09:00-09:25 How to move forward from LDCT screening J. Field, UK 09:25-09:55 Cancer prevention: From challenges in smoking cessation to the implementation of screening programmes J.L. Mulshine, IL/US 09:55-10:20 Cost-effectiveness of the prevention of lung cancer W. Evans, CA 10:20-10:30 Questions and Answers
5 10:30-11:00 Coffee break Hall 1 11:00-12:30 The difficult targets: KRAS, PIK3CA and FRGF1/2 Room B 11:00-11:20 KRAS G. Giaccone, MD/US 11:20-11:40 PIK3CA M. Schuler, DE 11:40-12:00 FRGF1/2 R. Camidge, CO/US 12:00-12:20 Future perspective on managing resistance mechanisms G. Giaccone, MD/US 12:20-12:30 Questions and Answers / Panel Discussion 11:00-12:30 Molecular characterisation of NSCLC: What should we really get for our patients? Room A 11:00-11:20 Targetable genome alterations in squamous cell lung cancer K. Park, KR 11:20-11:40 Tracking lung cancer genome evolution under targeted therapy I. Wistuba, TX/US 11:40-12:00 Novel insights into genome alterations of small cell lung cancer J. George, DE 12:00-12:20 Targeting developmental pathways in small cell lung cancer A.A. Adjei, NY/US 12:20-12:30 Questions and Answers / Panel Discussion
6 11:00-12:30 Radiation Oncology NSCLC: Current developments and state-of-the-art Room C 11:00-11:20 SBRT for stage I S. Senan, NL 11:20-11:40 Stage IIIA: Trimodal versus radiochemotherapy M. Stuschke, DE 11:40-12:00 Stage IIIB: Primary radiochemotherapy R. Dziadziuszko, PL 12:00-12:20 Radiation therapy for oligometastatic disease M. Guckenberger, CH 12:20-12:30 Questions and Answers / Panel Discussion 11:00-12:30 Sublobar resections: When and how Room X 11:00-11:20 The current value of wedge resections D. Wood, WA/US 11:20-11:40 Technical aspects of sublobar resection and oncological indications H. Asamura, JP 11:40-12:00 Length of stay and postoperative morbidity D. Gossot, FR 12:00-12:20 Quality of sub lobar resections D. Waller, UK 12:20-12:30 Questions and Answers / Panel Discussion
7 11:00-12:30 New frontiers in endoscopy Room W 11:00-11:20 Bronchoscopy in the era of early and screen detected peripheral nodules C. Dooms, BE 11:20-11:40 In vivo cellular imaging of lung cancer L. Thiberville, FR 11:40-12:00 Endobronchial treatment and follow up of malignant central airway obstruction K. Darwiche, DE 12:00-12:20 Diagnostic and therapeutic approach(es) to malignant pleural effusion N. Peled, IL 12:20-12:30 Questions and Answers / Panel Discussion 12:30-13:00 Poster lunch Hall 1 13:00-14:00 Industry Satellite Symposium 3 (TBC) Room A 14:10-14:40 Basic immunotherapy for current and future cancer treatment strategies Room B 14:10-14:40 Basic immunotherapy for current and future cancer treatment strategies J. Haanen, NL 14:45-16:15 Proffered Papers 1 Room B
8 14:45-16:15 Radiotherapeutic issues of dose and fractionation Room A 14:45-15:05 Current state-of-the-art and future directions of time/dose/fractionation for radio(chemo)therapy of lung cancer J. Belderbos, NL 15:05-15:25 Optimizing the therapeutic ratio using novel radiotherapy technology D. De Ruysscher, BE 15:25-15:45 Peripheral, central and too-central: Tumour location and practice of SBRT in early stage NSCLC U. Nestle, DE 15:45-16:05 Efficacy of SBRT: Just an issue of dose or different radiobiology? N. Andratschke, CH 16:05-16:15 Questions and Answers 14:45-16:00 Poster Discussion 1 Room W 16:15-16:45 Coffee break Hall 1 16:45-18:00 Poster Discussion 2 Room W 18:40-19:40 Industry Satellite Symposium 4 (TBC) Room A 18:40-19:40 Industry Satellite Symposium 5 (TBC) Room C :00-08:50 Combining TKI with other strategies Room A 08:00-08:15 Targeted agents and radiotherapy in locally advanced disease F. Mornex, FR 08:15-08:30 The role of local therapies in advanced molecular-driven NSCLC J. Vansteenkiste, BE 08:30-08:50 Discussion 08:00-08:50 Young Oncologists 2 Room X
9 08:00-08:50 PCI in SCLC and NSCLC Room W 08:00-08:15 Current controversies in SCLC T. Seto, JP 08:15-08:30 Any role in NSCLC C. Le Péchoux, FR 08:30-08:50 Discussion 09:00-10:30 Immunotherapy Room B 09:00-09:20 Immunotherapy as a new standard of care in NSCLC M. Reck, DE 09:20-09:40 Immunotherapy in thoracic malignancies beyond NSCLC S. Peters, CH 09:40-10:00 Clinical trial designs and ongoing trials in thoracic immune-oncology D. Carbone, OH/US 10:00-10:20 The quest for an immunotherapy biomarker K. Kerr, UK 10:20-10:30 Questions and Answers 09:00-10:30 Proffered Papers 3 Room C 10:30-11:00 Coffee break Hall 1
10 11:00-12:30 How to improve stage III NSCLC multimodality treatment Room B 11:00-11:20 Recent developments in the landscape of stage III K.S. Albain, IL/US 11:20-11:40 Radiotherapy innovations relevant for stage III M. Stuschke, DE 11:40-12:00 Surgical techniques relevant for stage III G. Stamatis, DE 12:00-12:20 Systemic treatment with future impact on stage III S. Peters, CH 12:20-12:30 Questions and Answers 11:00-12:30 New molecular targets of interest Room A 11:00-11:20 B-RAF D. Planchard, FR 11:20-11:40 RET J. Wolf, DE 11:40-12:00 FGFR1 R. Camidge, CO/US 12:00-12:20 HER2 E. Felip, ES 12:20-12:30 Questions and Answers
11 11:00-12:30 Thymic malignancy: An update Room C 11:00-11:20 Signal conduction pathways in thymic malignancies Y. Ohe, JP 11:20-11:40 Systemic approaches to thymic malignancies: State of the art N. Girard, FR 11:40-12:00 Surgical management of thymic malignancies E. Ruffini, IT 12:00-12:20 Pathology diagnoses in thymic malignancies A. Marx, DE 12:20-12:30 Questions and Answers 12:30-13:00 Poster lunch Hall 1 13:00-14:00 Industry Satellite Symposium 6 (TBC) Room A 13:00-14:00 Industry Satellite Symposium 7 (TBC) Room C 14:10-14:40 (History of) Platinum in lung cancer Room B 14:10-14:40 (History of) Platinum in lung cancer L.H. Einhorn, IN/US 14:45-16:00 Poster Discussion 3 Room W 16:15-16:45 Coffee break Hall 1 16:45-18:15 ESMO-IASLC Best Abstracts Room B
12 16:45-18:15 Collaborative efforts for rare molecularly defined NSCLC Room A 16:45-17:05 Building TCGA and alchemist networks R. Govindan, MO/US 17:05-17:25 The SPECTAlung program B. Besse, FR 17:25-17:45 The Lungscape program R.A. Stahel, CH 17:45-18:05 The SAFIR umbrella trial F. Barlesi, FR 18:05-18:15 Questions and Answers 16:45-18:15 Special session (TBC) Room W 18:40-19:40 Industry Satellite Symposium 8 (TBC) Room A 18:40-19:40 Industry Satellite Symposium 9 (TBC) Room C :45-09:15 Lung cancer care: The last and the next 5 years perspectives Room A 08:45-09:15 Lung cancer care: The last and the next 5 years perspectives J.-C. Soria, FR
13 09:20-10:50 WHO 2015 Room A 09:20-09:40 Impact of the new classification: The pathologist s view K. Kerr, UK 09:40-10:00 Impact of the new classification: The surgeon s view P. Van Schil, BE 10:00-10:20 Neuroendocrine tumours: Update and controversies W. Travis, NY/US 10:20-10:40 WHO2015: Small sample diagnosis in lung cancer E. Brambilla, FR 10:40-10:50 Questions and Answers 10:50-11:20 Coffee break Hall 1 11:20-12:50 Minimally invasive local approaches Room A 11:20-11:40 Measures to improve outcomes after surgery J. Kuzdzal, PL 11:40-12:00 Organ sparing surgery: Sublobar anatomical resection versus lobectomy? S. Welter, DE 12:00-12:20 Evaluating surgery versus SABR in clinical trials: New insights K. Franks, UK 12:20-12:40 A patients perspective on outcomes D. Timmermans, NL 12:40-12:50 Questions and Answers 12:50-13:00 Closing remarks Room A Chair: W. Eberhardt, DE; S. Peters, CH
:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B
04-10-2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
W. Eberhardt, Essen, DE. M. Pless, Winterthur, CH. D. De Ruysscher, Maastricht, NL. Moderation: R. Rami-Porta, Terrassa, Barcelona/ES
10.04.2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
EORTC LUNG CANCER GROUP GROUP MEETING
Sunday 7 th October 2018 Time slot Topic / Title of presentation Chair 9.00 11.00 Board meeting 11.00 11.30 Arrivals & Welcome coffee 11.30 11.50 Welcome & Introduction New Board,, Membership status, Calendar
FALL MEETING. Sitges, 7th and 8th October, Venue. ME Sitges Terramar Hotel Passeig Marítim, Sitges, Barcelona
FALL MEETING Sitges, 7th and 8th October, 2018 Venue ME Sitges Terramar Hotel Passeig Marítim, 80 08870 Sitges, Barcelona Sunday 7 th October 2018 Time slot Topic / Title of presentation Chair 9.00 11.00
October 12 13, 2018 New York Marriott Marquis New York, New York. The premier conference for annual updates in lung cancer. 23rd Annual Conference
The premier conference for annual updates in lung cancer 23rd Annual Conference October 12 13, 2018 New York Marriott Marquis New York, New York Reserve your place today: thoraciccancermeeting.com Perspectives
Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404
23-11-2018 10:00-11:30 Type: Opening session Title: Opening & Keynote Hall 406 11:45-12:30 Type: Challenge Your Expert session Title: Treatment of node positive bladder 11:45-11:55 Treatment of node positive
8 th European Lung Cancer Congress (ELCC) Geneva, Switzerland, April 2018 PROGRAMME. Wednesday, 11 April Industry Satellite Symposium 1
8 th European Lung Cancer Congress (ELCC) Geneva, Switzerland, 11-14 April 2018 PROGRAMME Wednesday, 11 April 2018 12:00-13:00 13:00-13:30 Hall 1 Industry Satellite Symposium 1 Welcome Reception 13:30-13:45
ESMO-Christie Lung Cancer Course
SMO-Christie Lung Cancer Course Wednesday 12th - Friday 14th February 2014 ducation Centre (Dept 17), The Christie, Manchester, M20 4BX This event is a joint initiative between The uropean Society for
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Program 7:15 7:40 Translocations as predictive biomarkers in lung cancer: Overview Mari Mino Kenudson, MD 7:40 8:05 Translocation
Amphithéâtre Bordeaux. Amphithéâtre. C. Massard, Villejuif, CEDEX/FR. N. Rizvi, New York, NY/US
25.02.2019 08:45-09:30 Opening and welcome + Honorary award Keynote lecture 08:45-08:55 Welcome address 08:55-09:00 Presentation of the TAT 2019 Honorary Award 09:00-09:30 TAT 2018 Honorary Award Keynote
MY LUNG CANCER CARE PLAN
MY LUNG CANCER CARE PLAN MANAGE DIAGNOSIS TRACK TREATMENTS & APPOINTMENTS MONITOR SYMPTOMS FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers We are Free
Day 1: ESMO Sarcoma & GIST Faculty closed meeting
Day 1: ESMO Sarcoma & GIST Faculty closed meeting Sunday, 4 February 2018 12:30 14:00 Lunch 14:00-16:00 Discussion: Should we routinely use NGS? 120 Panel discussion 16:00 16:30 Coffee Break 16:30-18:00
Preliminary Agenda. 9:55-10:20 How to overcome TKI resistance? James Chih-Hsin Yang 10:20-10:40 Discussion All 10:40-10:55 Coffee break
Preliminary Agenda November 7, 2018 14:00-17:00 Registration and check in Satellite Symposia with Dinner 17:00-18:30 Jiangsu Hengrui Medicine Co., Ltd 17:00-18:30 Satellite Symposia with Dinner 17:00-18:30
Practice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
Treatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
Histopathology of NSCLC, IHC markers and ptnm classification
ESMO Preceptorship on Non-Small Cell Lung Cancer November 15 th & 16 th 2017 Singapore Histopathology of NSCLC, IHC markers and ptnm classification Prof Keith M Kerr Department of Pathology, Aberdeen University
D Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
2016 CRUK Lung Cancer Centre of Excellence Student/Postdoc Winter Workshop Programme
2016 CRUK Lung Cancer Centre of Excellence Student/Postdoc Winter Workshop Programme Thursday 1 st December 2016 09.15am 10.00am Registration and Refreshments 10.15am 10.30am Welcome 10.30am 11.15am Opening
Berlin. Title: Industry Satellite Symposium. Vienna. Title: Industry Satellite Symposium. Exhibition area. Title: Welcome reception
02.05.2019 12:00-13:00 Type: Industry Satellite Symposium 12:00-13:00 Type: Industry Satellite Symposium 13:00-13:30 Type: Opening session Title: Welcome reception Exhibition area 13:30-13:45 Type: Opening
RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
ESTS SCHOOL FIRST ESTS-ERS COLLABORATIVE COURSE ON THORACIC ONCOLOGY A MULTIDISCIPLINARY UPDATE ON POTENTIALLY OPERABLE LUNG CANCER
SCHOOL FIRST -ERS COLLABORATIVE COURSE ON ONCOLOGY A MULTIDISCIPLINARY UPDATE ON POTENTIALLY OPERABLE LUNG CANCER 11-13 February 2019 Hamburg, Germany An application will be made for accreditation to European
Medical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
http://www.eortc.org/carefor/ Brussels, October 14 2015 Which organizations do clinical research? Pharmaceutical industry [in vitro]medical device industry Academic sponsors Universities & hospitals Networks
ETOP NLCFN BTS AILCF (Confirmed) ESMO (To be confirmed)
10 th Annual BTOG Conference 2012 Venue: Fitzwilliam Hall, The Burlington Hotel, Dublin Wednesday 25 th to Friday 27 th January 2012 Continuing Professional Development Accreditation applied for from the
MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE
25 th IAP-Arab Division Conference 07-09 November 2013, Amman, Jordan MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE Fouad Al Dayel, MD, FRCPA, FRCPath Professor and Chairman Department
ACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
17:00 17:45 Meet-the-Professor Immuno-Oncology Fan Yang, Beijing, Christoph Zielinski, Vienna
8 th Chinese German Lung Cancer Forum Dresden, Germany, September 8-10, 2016 Precision oncology in lung cancer Thursday, September 8, 2016 17:00 17:45 Meet-the-Professor Immuno-Oncology Fan Yang, Beijing,
Molecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
Shyam B. Paryani M.D., M.S., M.H.A & Nitesh N. Paryani, M.D. May 1 st, th Annual Cardiovascular & Medicine Symposium St. Augustine, Florida
Shyam B. Paryani M.D., M.S., M.H.A & Nitesh N. Paryani, M.D. May 1 st, 2015 16 th Annual Cardiovascular & Medicine Symposium St. Augustine, Florida Outline Terminology & Background A brief historical overview
Personalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
Surgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
Dr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
THORACIC SURGICAL ONCOLOGY
Call for Abstracts Submission deadline: August 2 Details inside* ADVANCES IN THORACIC SURGICAL ONCOLOGY October 2-3, 2015 COURSE LOCATION Waldorf Astoria Hotel 301 Park Avenue New York For more information
8/22/2016. Major risk factors for the development of lung cancer are: Outline
Carcinomas of the Lung: Changes in Staging, Adenocarcinoma Classification and Genetics Grace Y. Lin, M.D., Ph.D. Outline Background Staging of Lung Cancer: Review of the 2010 7 th Edition of the AJCC Cancer
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
Joachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
Weitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
New Therapeutic Strategies in Lung Cancers
New Therapeutic Strategies in Lung Cancers Solange Peters Benjamin Besse Editors New Therapeutic Strategies in Lung Cancers Editors Solange Peters Oncology Centre Hospitalier Universitaire Vaudois Lausanne
Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
Improving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
The 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
Early and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
October 6-7, 2017 Marseille, France
Program Chairs M. Ahluwalia (US) E. Le Rhun (FR) P. Métellus (FR) M. Weller (CH) Scientific Committee M. Ahluwalia (US) Z. Ram (IL) F. Dhermain (FR) R. Soffietti (IT) E. Le Rhun (FR) M. Weller (CH) P.
Imaging evaluation of response in NSCLC R. Efthymiadou. Minimal thoracic surgery-maximum efficacy. What new in 2018 K. Iliadis
I N T Lung Cancer Seminar E R N A T I O N A L friday September 14, 2018 14.00-15.00 Registration opens 15.00-15.30 LECTURE I Chairpersons: V. Iordanoglou, Ch. Marinou Smoking and lung cancer epidemiology
Innovations in Lung Cancer Diagnosis and Surgical Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
PRECEPTORSHIP PROGRAMME
esmo.org PRECEPTORSHIP PROGRAMME Gastrointestinal Tumours Multidisciplinary management, standards of care and future perspectives SINGAPORE 20-22 OCTOBER 2016 Co-Chairs Jean-Yves Douillard, Switzerland
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
Case Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
Melanoma Summit. DRAFT programme. New Zealand November 2018 Cordis Hotel, Auckland. As at 1 September Subject to change.
Melanoma Summit New Zealand 2018 2 3 November 2018 Cordis Hotel, Auckland DRAFT programme As at 1 September 2018 Subject to change. Friday 2 November 2018 TIME TOPIC PRESENTER 0830 Mihi whakatau 0845 Formal
Charles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy
REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group OUR 10 MESSAGE HIGHLIGHTS 1/ Advanced NSCLC 1 st line: IO
Monday, 5 February 2018
Educational sessions for Junior audience Monday, 5 February 2018 09:30-11:00 Session 1 The diseases Chairs: Paolo. G Casali, IT; Paula Collini, IT 25 The natural history of STS & GIST Paolo. G Casali,
Infographic (right): ESMO 2014 record breaking Congress
ESMO 2014 Congress Scientific Meeting Report Precision Medicine in Cancer Care 26-30 September 2014 Madrid, Spain Summary The European Society for Medical Oncology (ESMO) Congress, held September 26 to
Scientific Meeting Report. Dr. Marina Garassino ESMO Publishing Working Group The 2nd European Lung Cancer Conference
Scientific Meeting Report. Dr. Marina Garassino ESMO Publishing Working Group The 2nd European Lung Cancer Conference Geneva 28 April 1 May 2010 Scientific Meeting Report Dr. Marina Garassino. ESMO Publishing
SCIENTIFIC TIMETABLE SIOP 2015
SCIENTIFIC TIMETABLE SIOP 2015 September, 2015 WEDNESDAY, 7 TH OCTOBER 2015 / DAY 2 1.43 09:30 SIOP Committee 12:00 SIOP Essential Drugs Working 13:00 SIOP Work (Open) 14:00 Nurse Researchers 16:00 17:00
07:00-07:10 Clinical potential of mirnas and their targets in NSCLC
9th European Regional Conference on Thoracic Oncology: New challenges in diagnosis and treatment 16-17 June 2017 Hotel Holiday Inn Vilnius Conference Program Friday, June 16, 2017 7:00 8:30 Young investigators
ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain
ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme 14-19 July 2016, Valencia, Spain Co-chairs: Andrés Cervantes, ES - Nicholas Pavlidis, GR - Susana Banerjee, UK Thursday, 14
Small-cell lung cancer (SCLC) represents approximately
Original Article Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn G. Hancock, BS, Daniel J. Boffa, MD,
LUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
Optimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
IMMERSION IN MINIMALLY INVASIVE THORACIC SURGERY. 28 August- 1 September 2017, Québec - Canada
IMMERSION IN MINIMALLY INVASIVE THORACIC SURGERY 28 August- 1 September 2017, Québec - Canada MONDAY 28/08/2017 - SYMPOSIUM: LOBAR X SUBLOBAR RESECTION 07:45 Welcome Dr. Simon Martel (CAN) and Dr. 08:00
SCOTTISH ONCOLOGY SUMMIT Double Tree by Hilton, Dunblane Hydro, Dunblane 1 st - 2 nd September 2017
Friday 1 st September 1300h 1400h Lunch (arrival, registration at conference foyer, coffee and sponsors exhibition) 1400h 1420h Prof Robert Jones Welcome/Announcements 1430h 1600h Parallel sessions: Lung
CME. Thoracic Malignancies. Annual Oncology Symposium: Friday, May 2, Glaser Auditorium Swedish/First Hill 747 Broadway Seattle, Washington
Annual Oncology Symposium: Thoracic Malignancies CME CONTINUING MEDICAL EDUCATION Friday, May 2, 2014 Glaser Auditorium Swedish/First Hill 747 Broadway Seattle, Washington Needs Statement The American
Multifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
Adam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
Best of WCLC- San Francisco
Best of WCLC- San Francisco Saturday, November 11, 2017 InterContinental San Francisco UC Davis Comprehensive UCSF Helen Diller Family Comprehensive A B Stanford University Cancer Institute David R. Gandara,
Perspectives on oligometastasis: challenges and opportunities
Editorial Perspectives on oligometastasis: challenges and opportunities Jana Heitmann, Matthias Guckenberger Department of Radiation Oncology, University Hospital Zürich, Zürich, Switzerland Correspondence
Lung Cancer 2017: November 4, 2017 Renaissance Washington, DC Dupont Circle Hotel
Lung Cancer 2017: November 4, 2017 Renaissance Dupont Circle Hotel Progress and Future Directions Course Directors: Giuseppe Giaccone, MD, PhD MedStar Georgetown Cancer Network CME INFORMATION COURSE DESCRIPTION
CHICAGO LUNG CANCER UPDATES 2018
NEW PROGRAM! CHICAGO LUNG CANCER UPDATES 2018 CONFERENCE CO-DIRECTORS Jyoti Patel, MD Everett Vokes, MD OMNI HOTEL 676 North Michigan Avenue Chicago, IL 60611 Register at: https://cme.uchicago.edu/clcu2018
Lung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten. W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.
N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.Senan Submitted 10 Salvage surgery for local failures after stereotactic
New Radiation Treatment Modalities in the Treatment of Lung Cancer
New Radiation Treatment Modalities in the Treatment of Lung Cancer David Perry, M.D. Chief, Radiation Oncology Medical Director, CyberKnife Radiosurgery Center Medstar Franklin Square Medical Center Definitions
International Symposium on Malignant Pleural Mesothelioma
International Symposium on Malignant Pleural Mesothelioma LONDON 2015 Friday 6th & Saturday 7th November 2015 Jumeirah Carlton Tower Hotel Cadogan Place Knightsbridge London SW1X 9PY United Kingdom Dear
Accepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
Changes in TNM-classification 7 th edition T T1 2 cm T1a
Introduction 1 Chapter 1 Introduction 9 Currently, cancer is the second leading cause of death in Europe 1. Globally, lung cancer is by far the most common cause of cancer-related deaths, and is by itself
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2014 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell
3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Lung Cancer T STAGE OUTLINE SURVIVAL ACCORDING TO SIZE ONLY
Pathologic Staging Updates in Lung Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH
27.04.2018 10:30-10:45 Opening and welcome Sala B Moderation: S. Rauh, J. Douillard ; Esch Sur Alzette, LU, Lugano - Viganello, CEDEX/CH 10:30-10:45 Welcome to the Symposium S. Rauh 1, J. Douillard 2 ;
New molecular targets in lung cancer therapy
New molecular targets in lung cancer therapy Giuseppe Pelosi Pathology Division, Science & Technology Park, IRCCS Multimedica, Milan Milan - Italy Advanced lung cancer (IIIB IV) Subtyping Oncogene addiction
Changing demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
An Interactive Guide to ALK+ Lymphoma. Our understanding of lung cancer has changed From one disease to many subtypes LCD
An Interactive Guide to ALK+ Anaplastic Lymphoma Kinase Non-Small Cell Lung (NSCLC) Our understanding of lung cancer has changed From one disease to many subtypes Click to get started Learning about Lung
Treatment of Multiple Lung Tumors
VUmc SABR Symposium 2017 Treatment of Multiple Lung Tumors Indications and Dosimetric Considerations Dr. David Palma, MD, MSc, PhD Radiation Oncologist, London Health Sciences Centre Clinician-Scientist,
LCA Lung Clinical Forum. 21 st October 2014
LCA Lung Clinical Forum 21 st October 2014 Welcome Dr Liz Sawicka Chair - LCA Lung Pathway Group Succession planning Dr Kate Haire Consultant in Public Health Medicine, LCA Commissioning Intentions for
Quale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
surgical approach for resectable NSCLC
surgical approach for resectable NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France 1933 Graham EA, Singer JJ.
Stereotactic ablative radiotherapy in early NSCLC and metastases
Stereotactic ablative radiotherapy in early NSCLC and metastases Scheduled: 0810-0830 hrs, 10 March 2012 Professor Suresh Senan Department of Radiation Oncology SABR in stage I NSCLC A major treatment
The 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice
The 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice University of Torino Lecture 28th June 2017 Torino, Italy Ramón Rami-Porta Thoracic
Lugano Switzerland May Multidisciplinary Thoracic Oncology. Programme Book. emcto.org
European Multidisciplinary Conference in Thoracic Oncology 2013 emcto.org European Multidisciplinary Conference in Thoracic Oncology Programme Book Lugano Switzerland 9-11 May 2013 Organisers 1 ESTS CONFERENCE
7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic